Read Gene SA
WSE:RDG

Watchlist Manager

Read Gene SA

WSE:RDG

Watchlist

Dividends

Discount Rate

Price: 4.9 PLN 1.66% Market Closed

Market Cap: 57.8m PLN

Have any thoughts about
Read Gene SA?

Write Note

Write Note Create Alert Ask AI

Add Note Why Create Notes?

Capture your thoughts

Note Buy Sell Hold Pass

US	Johnson & Johnson NYSE:JNJ	Pharmaceuticals
US	Estee Lauder Companies Inc NYSE:EL	Consumer products
US	Exxon Mobil Corp NYSE:XOM	Energy
US	Church & Dwight Co Inc NYSE:CHD	Consumer products
US	Pfizer Inc NYSE:PFE	Pharmaceuticals
US	American Express Co NYSE:AXP	Financial Services
US	Nike Inc NYSE:NKE	Textiles, Apparel & Luxury Goods
US	Visa Inc NYSE:V	Technology
CN	Alibaba Group Holding Ltd NYSE:BABA	Retail
US	3M Co NYSE:MMM	Industrial Conglomerates
US	JPMorgan Chase & Co NYSE:JPM	Banking
US	Coca-Cola Co NYSE:KO	Beverages
US	Target Corp NYSE:TGT	Retail
US	Walt Disney Co NYSE:DIS	Media
US	Mueller Industries Inc NYSE:MLI	Machinery
US	PayPal Holdings Inc NASDAQ:PYPL	Technology

Add Price Alert

Price Target:

Last Price: 4.9 PLN

We'll email you a reminder when the closing price reaches USD.

If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.

Peter Lynch

Track and Analyze Performance

Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.

Continuous Learning and Adaptation

Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.

Boost Decision Confidence

With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.

Why create notes?

Back

Delete Note

Do you really want to delete this note?
This action cannot be undone.

Remove price alert for reaching

Delete

Cancel

RDG Alert

Read Gene SA

4.9

+0.08 (+1.66%)

52 Week Range	3.2 6.6
Price Target

We'll email you a reminder when the closing price reaches PLN.

Save Alert

Choose the stock you wish to monitor with a price alert.

	Johnson & Johnson NYSE:JNJ	US
	Estee Lauder Companies Inc NYSE:EL	US
	Exxon Mobil Corp NYSE:XOM	US
	Church & Dwight Co Inc NYSE:CHD	US
	Pfizer Inc NYSE:PFE	US
	American Express Co NYSE:AXP	US
	Nike Inc NYSE:NKE	US
	Visa Inc NYSE:V	US
	Alibaba Group Holding Ltd NYSE:BABA	CN
	3M Co NYSE:MMM	US
	JPMorgan Chase & Co NYSE:JPM	US
	Coca-Cola Co NYSE:KO	US
	Target Corp NYSE:TGT	US
	Walt Disney Co NYSE:DIS	US
	Mueller Industries Inc NYSE:MLI	US
	PayPal Holdings Inc NASDAQ:PYPL	US

Delete Alert

This alert will be permanently deleted.

Remove note

Delete

Cancel

Ask me anything about

Read Gene SA

What unique competitive advantages
does Read Gene SA hold over its rivals?

What risks and challenges
does Read Gene SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Provide an overview of the primary business activities
of Read Gene SA.

What unique competitive advantages
does Read Gene SA hold over its rivals?

What risks and challenges
does Read Gene SA face in the near future?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Read Gene SA.

Provide P/S
for Read Gene SA.

Provide P/E
for Read Gene SA.

Provide P/OCF
for Read Gene SA.

Provide P/FCFE
for Read Gene SA.

Provide P/B
for Read Gene SA.

Provide EV/S
for Read Gene SA.

Provide EV/GP
for Read Gene SA.

Provide EV/EBITDA
for Read Gene SA.

Provide EV/EBIT
for Read Gene SA.

Provide EV/OCF
for Read Gene SA.

Provide EV/FCFF
for Read Gene SA.

Provide EV/IC
for Read Gene SA.

Compare the intrinsic valuations
of Read Gene SA and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Read Gene SA against its competitors.

Analyze the profit margins
(gross, operating, and net) of Read Gene SA compared to its peers.

Compare the P/E ratios
of Read Gene SA against its peers.

Discuss the investment returns and shareholder value creation
comparing Read Gene SA with its peers.

Analyze the financial leverage
of Read Gene SA compared to its main competitors.

Show all profitability ratios
for Read Gene SA.

Provide ROE
for Read Gene SA.

Provide ROA
for Read Gene SA.

Provide ROIC
for Read Gene SA.

Provide ROCE
for Read Gene SA.

Provide Gross Margin
for Read Gene SA.

Provide Operating Margin
for Read Gene SA.

Provide Net Margin
for Read Gene SA.

Provide FCF Margin
for Read Gene SA.

Show all solvency ratios
for Read Gene SA.

Provide D/E Ratio
for Read Gene SA.

Provide D/A Ratio
for Read Gene SA.

Provide Interest Coverage Ratio
for Read Gene SA.

Provide Altman Z-Score Ratio
for Read Gene SA.

Provide Quick Ratio
for Read Gene SA.

Provide Current Ratio
for Read Gene SA.

Provide Cash Ratio
for Read Gene SA.

What is the historical Revenue growth
over the last 5 years for Read Gene SA?

What is the historical Net Income growth
over the last 5 years for Read Gene SA?

What is the current Free Cash Flow
of Read Gene SA?

Discuss the annual earnings per share (EPS)
trend over the past five years for Read Gene SA.

P/S
Price to Sales

Current

4.9

Median

8.1

Industry

Higher than median

Lower than industry value

Price to Sales (P/S) ratio is a valuation multiple that compares a company’s market capitalization to its revenues. It is an indicator of the value that financial markets have placed on each dollar of a company’s sales.

P/S

Market Cap

57.8m PLN

Revenue

11.6m PLN

All Countries

Forward Multiples

			Market Cap	P/S
PL	R	Read Gene SA WSE:RDG	57.8m PLN	5
FR		Pharnext SCA OTC:PNEXF	6T USD	37 678 545.3
US		Abbvie Inc NYSE:ABBV	299.8B USD	5.4
US		Amgen Inc NASDAQ:AMGN	159.1B USD	4.9
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	124.7B USD	11.7
US		Gilead Sciences Inc NASDAQ:GILD	114.8B USD	4.1
US	E	Epizyme Inc F:EPE	94.1B EUR	1 869.7
AU		CSL Ltd ASX:CSL	137.3B AUD	6
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	86.2B USD	6.2
US	S	Seagen Inc F:SGT	39.3B EUR	18
NL		argenx SE XBRU:ARGX	34B EUR	18.4

				Revenue Growth
PL	R	Read Gene SA WSE:RDG	Average P/S: 3 425 499.5 5	N/A
FR		Pharnext SCA OTC:PNEXF	37 678 545.3	N/A
US		Abbvie Inc NYSE:ABBV	5.4	20%
US		Amgen Inc NASDAQ:AMGN	4.9	26%
US		Vertex Pharmaceuticals Inc NASDAQ:VRTX	11.7	33%
US		Gilead Sciences Inc NASDAQ:GILD	4.1	10%
US	E	Epizyme Inc F:EPE	1 869.7	N/A
AU		CSL Ltd ASX:CSL	6	23%
US		Regeneron Pharmaceuticals Inc NASDAQ:REGN	6.2	23%
US	S	Seagen Inc F:SGT	18	118%
NL		argenx SE XBRU:ARGX	18.4	220%

P/S Forward Multiples

Forward P/S multiple is a version of the P/S ratio that uses forecasted revenue for the P/S calculation. 1-Year, 2-Years, and 3-Years forwards use revenue forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward

P/S

N/A

2-Years Forward

P/S

N/A

3-Years Forward

P/S

N/A

Read Gene SA
WSE:RDG

P/S
Price to Sales

P/S Forward Multiples

See Also

Company

Help

Tools

Stocks

Read Gene SA WSE:RDG

P/S Price to Sales

P/S Forward Multiples

See Also

Company

Help

Tools

Stocks

Read Gene SA
WSE:RDG

P/S
Price to Sales